The US Supreme Court has temporarily upheld access to the abortion pill, mifepristone, by mail, which is crucial for women in states with restrictive abortion laws. This decision extends a temporary block on the ruling made by an ultraconservative appeals court on May 1, allowing American women to access the abortion pill directly via mail until the Supreme Court, majority conservative, decides whether to take up the case. The court had until Thursday to consider the legal challenge filed by Danco and GenBioPro, manufacturers of mifepristone, a medication used in medical abortions, representing nearly two-thirds of abortions in the US in 2023.
At least two conservative judges, Samuel Alito and Clarence Thomas, expressed disagreement with the decision. The decision has brought relief to many but concerns remain among abortion rights advocates, especially given the current political landscape.
This legal battle and the FDA’s safety review of mifepristone under pressure from anti-abortion groups highlight the continued challenges to access to this medication. Despite the temporary victory, the fight for reproductive rights continues in the US, where access to safe and legal abortion remains a critical issue.
